vs
NEUROCRINE BIOSCIENCES INC（NBIX）与Reddit, Inc.（RDDT）财务数据对比。点击上方公司名可切换其他公司
NEUROCRINE BIOSCIENCES INC的季度营收约是Reddit, Inc.的1.1倍（$805.5M vs $725.6M），Reddit, Inc.净利率更高（34.7% vs 19.1%，领先15.6%），Reddit, Inc.同比增速更快（69.7% vs 28.3%），NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $263.6M），过去两年Reddit, Inc.的营收复合增速更高（72.8% vs 25.0%）
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
NBIX vs RDDT — 直观对比
营收规模更大
NBIX
是对方的1.1倍
$725.6M
营收增速更快
RDDT
高出41.3%
28.3%
净利率更高
RDDT
高出15.6%
19.1%
自由现金流更多
NBIX
多$122.4M
$263.6M
两年增速更快
RDDT
近两年复合增速
25.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $805.5M | $725.6M |
| 净利润 | $153.7M | $251.6M |
| 毛利率 | 97.8% | 91.9% |
| 营业利润率 | 26.2% | 31.9% |
| 净利率 | 19.1% | 34.7% |
| 营收同比 | 28.3% | 69.7% |
| 净利润同比 | 49.1% | 254.2% |
| 每股收益（稀释后） | $1.49 | $1.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NBIXRDDT
| Q4 25 | $805.5M | $725.6M | ||
| Q3 25 | $794.9M | $584.9M | ||
| Q2 25 | $687.5M | $499.6M | ||
| Q1 25 | $572.6M | $392.4M | ||
| Q4 24 | $627.7M | $427.7M | ||
| Q3 24 | $622.1M | $348.4M | ||
| Q2 24 | $590.2M | $281.2M | ||
| Q1 24 | $515.3M | $243.0M |
净利润NBIXRDDT
| Q4 25 | $153.7M | $251.6M | ||
| Q3 25 | $209.5M | $162.7M | ||
| Q2 25 | $107.5M | $89.3M | ||
| Q1 25 | $7.9M | $26.2M | ||
| Q4 24 | $103.1M | $71.0M | ||
| Q3 24 | $129.8M | $29.9M | ||
| Q2 24 | $65.0M | $-10.1M | ||
| Q1 24 | $43.4M | $-575.1M |
毛利率NBIXRDDT
| Q4 25 | 97.8% | 91.9% | ||
| Q3 25 | 98.2% | 91.0% | ||
| Q2 25 | 98.4% | 90.8% | ||
| Q1 25 | 98.4% | 90.5% | ||
| Q4 24 | 98.5% | 92.6% | ||
| Q3 24 | 98.7% | 90.1% | ||
| Q2 24 | 98.4% | 89.5% | ||
| Q1 24 | 98.5% | 88.6% |
营业利润率NBIXRDDT
| Q4 25 | 26.2% | 31.9% | ||
| Q3 25 | 30.1% | 23.7% | ||
| Q2 25 | 21.2% | 13.6% | ||
| Q1 25 | 4.1% | 1.0% | ||
| Q4 24 | 22.6% | 12.4% | ||
| Q3 24 | 29.5% | 2.0% | ||
| Q2 24 | 24.6% | -11.0% | ||
| Q1 24 | 19.3% | -242.5% |
净利率NBIXRDDT
| Q4 25 | 19.1% | 34.7% | ||
| Q3 25 | 26.4% | 27.8% | ||
| Q2 25 | 15.6% | 17.9% | ||
| Q1 25 | 1.4% | 6.7% | ||
| Q4 24 | 16.4% | 16.6% | ||
| Q3 24 | 20.9% | 8.6% | ||
| Q2 24 | 11.0% | -3.6% | ||
| Q1 24 | 8.4% | -236.7% |
每股收益（稀释后）NBIXRDDT
| Q4 25 | $1.49 | $1.24 | ||
| Q3 25 | $2.04 | $0.80 | ||
| Q2 25 | $1.06 | $0.45 | ||
| Q1 25 | $0.08 | $0.13 | ||
| Q4 24 | $1.00 | $4.76 | ||
| Q3 24 | $1.24 | $0.16 | ||
| Q2 24 | $0.63 | $-0.06 | ||
| Q1 24 | $0.42 | $-8.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $713.0M | $953.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.3B | $2.9B |
| 总资产 | $4.6B | $3.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NBIXRDDT
| Q4 25 | $713.0M | $953.6M | ||
| Q3 25 | $340.2M | $911.7M | ||
| Q2 25 | $264.0M | $734.1M | ||
| Q1 25 | $194.1M | $635.7M | ||
| Q4 24 | $233.0M | $562.1M | ||
| Q3 24 | $349.1M | $515.9M | ||
| Q2 24 | $139.7M | $468.0M | ||
| Q1 24 | $396.3M | $968.5M |
股东权益NBIXRDDT
| Q4 25 | $3.3B | $2.9B | ||
| Q3 25 | $3.0B | $2.6B | ||
| Q2 25 | $2.7B | $2.4B | ||
| Q1 25 | $2.5B | $2.2B | ||
| Q4 24 | $2.6B | $2.1B | ||
| Q3 24 | $2.7B | $2.0B | ||
| Q2 24 | $2.5B | $1.9B | ||
| Q1 24 | $2.4B | $1.8B |
总资产NBIXRDDT
| Q4 25 | $4.6B | $3.2B | ||
| Q3 25 | $4.3B | $2.9B | ||
| Q2 25 | $3.9B | $2.6B | ||
| Q1 25 | $3.7B | $2.4B | ||
| Q4 24 | $3.7B | $2.3B | ||
| Q3 24 | $3.5B | $2.2B | ||
| Q2 24 | $3.3B | $2.1B | ||
| Q1 24 | $3.5B | $2.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $388.4M | $266.8M |
| 自由现金流经营现金流 - 资本支出 | $386.0M | $263.6M |
| 自由现金流率自由现金流/营收 | 47.9% | 36.3% |
| 资本支出强度资本支出/营收 | 0.3% | 0.4% |
| 现金转化率经营现金流/净利润 | 2.53× | 1.06× |
| 过去12个月自由现金流最近4个季度 | $743.9M | $684.2M |
8季度趋势，按日历期对齐
经营现金流NBIXRDDT
| Q4 25 | $388.4M | $266.8M | ||
| Q3 25 | $227.5M | $185.2M | ||
| Q2 25 | $102.0M | $111.3M | ||
| Q1 25 | $64.8M | $127.6M | ||
| Q4 24 | $242.5M | $90.0M | ||
| Q3 24 | $158.0M | $71.6M | ||
| Q2 24 | $64.6M | $28.4M | ||
| Q1 24 | $130.3M | $32.1M |
自由现金流NBIXRDDT
| Q4 25 | $386.0M | $263.6M | ||
| Q3 25 | $214.3M | $183.1M | ||
| Q2 25 | $89.5M | $110.8M | ||
| Q1 25 | $54.1M | $126.6M | ||
| Q4 24 | $235.2M | $89.2M | ||
| Q3 24 | $149.9M | $70.3M | ||
| Q2 24 | $53.0M | $27.2M | ||
| Q1 24 | $119.1M | $29.2M |
自由现金流率NBIXRDDT
| Q4 25 | 47.9% | 36.3% | ||
| Q3 25 | 27.0% | 31.3% | ||
| Q2 25 | 13.0% | 22.2% | ||
| Q1 25 | 9.4% | 32.3% | ||
| Q4 24 | 37.5% | 20.8% | ||
| Q3 24 | 24.1% | 20.2% | ||
| Q2 24 | 9.0% | 9.7% | ||
| Q1 24 | 23.1% | 12.0% |
资本支出强度NBIXRDDT
| Q4 25 | 0.3% | 0.4% | ||
| Q3 25 | 1.7% | 0.4% | ||
| Q2 25 | 1.8% | 0.1% | ||
| Q1 25 | 1.9% | 0.2% | ||
| Q4 24 | 1.2% | 0.2% | ||
| Q3 24 | 1.3% | 0.4% | ||
| Q2 24 | 2.0% | 0.4% | ||
| Q1 24 | 2.2% | 1.2% |
现金转化率NBIXRDDT
| Q4 25 | 2.53× | 1.06× | ||
| Q3 25 | 1.09× | 1.14× | ||
| Q2 25 | 0.95× | 1.25× | ||
| Q1 25 | 8.20× | 4.88× | ||
| Q4 24 | 2.35× | 1.27× | ||
| Q3 24 | 1.22× | 2.40× | ||
| Q2 24 | 0.99× | — | ||
| Q1 24 | 3.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
RDDT
| Advertising | $689.7M | 95% |
| Other Revenue | $35.9M | 5% |
